Oracle Thermo Fisher Scientific Announces The Launch Of The EXENT Solution With IVDR Certification
Portfolio Pulse from Benzinga Newsdesk
Thermo Fisher Scientific has announced the commercial launch of the EXENT Solution, a mass spectrometry system designed to transform diagnosis and assessment for patients with monoclonal gammopathies, including multiple myeloma. The system is now available in several European countries. The EXENT Solution was developed with Mayo Clinic intellectual property and is intended to aid diagnosis of monoclonal gammopathies and monitoring of multiple myeloma and Waldenström's macroglobulinemia patients. Earlier this year, Thermo Fisher Scientific completed the acquisition of The Binding Site, adding protein diagnostics solutions to its specialty diagnostics portfolio.
August 24, 2023 | 12:19 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Thermo Fisher Scientific's launch of the EXENT Solution could potentially increase its market share in the diagnostics sector, especially in the European market where the product is now available. The acquisition of The Binding Site earlier this year also strengthens its position in the protein diagnostics solutions market.
The launch of a new product, especially one that addresses an unmet clinical need, can potentially increase a company's market share and revenues. The fact that the product is now available in several European countries also expands Thermo Fisher Scientific's reach in the global market. Additionally, the acquisition of The Binding Site earlier this year adds to its portfolio of protein diagnostics solutions, further strengthening its position in the market.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100